Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06670677

Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk

Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A. to correlate for the first time continual Blood Pressure monitoring and the evolution of environmental and health factors to improve hypertension management.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Fully remote study- no physical investigational site, Lausanne, Switzerland

Loading trial locations.

About this study

ARM 1:

N1~ 3'300 subjects.

Research participants are Aktiia G1 users with Android operating system, i.e. individuals who already purchased the Aktiia G1 device out of the context of the study, located in Switzerland, Germany or UK, and owning a smartphone with Android operating system. ARM 1 research participants are asked to:

  • For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project,
  • For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment.
  • Additionally, once the Aktiia One App is released and for the next 10 years:
  • Take an on-demand measurement with the Aktiia G2C feature (finger measurement) while seated.

ARM 2:

N2~ 6'600 subjects.

Research participants are Aktiia G1 users with iOS operating system, i.e. individuals who already purchased the Aktiia G1 device out of the context of the study, located in Switzerland, Germany or UK, and owning a smartphone with iOS operating system. ARM 2 research participants are asked to:

  • For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project,
  • For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
  • Additionally, once the Aktiia One App is released and for the next 10 years:
  • Take an on-demand measurement with the Aktiia G2C feature (finger measurement) while seated.

ARM 3:

N3~ 5'000 subjects.

Research participants are non-Aktiia-G1 users (they do not own an Aktiia G1 device at their inclusion in the study), located in Switzerland, Germany or UK, and owning a smartphone with either iOS or Android operating system. ARM 3 research participants are asked to:

  • For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
  • At their inclusion in the study: download the Aktiia One App to access G2C functionality with on-demand measurements at fingertip using the smartphone's camera.
  • For the next 10 years, starting at their inclusion in the research project and thereafter:
  • Take unlimited on-demand measurements with the Aktiia G2C feature.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult subjects aged 21 to 85 years old
  • Subjects living in Switzerland, Germany or in the UK
  • Subjects that are:

Aktiia users owning a smartphone with either iOS or Android operating system (ARMs 1 and 2); or Aktiia non-users owning a smartphone with iOS or Android operating system (ARM 3)

  • Subjects agreeing to follow the study procedures.

Exclusion criteria

  • Subjects suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including resting tachycardia (heart rate at rest > 120bpm) and atrial fibrillation;
  • Subjects suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR < 30mL / min / 1.73 m2), untreated hyper-/ hypothyroidism, pheochromocytoma, or arteriovenous fistula;
  • Subjects suffering from polyneuropathy;
  • on pregnant women;
  • Subjects with damaged / injured skin at the wrists (for bracelet measurements) or at index fingers (for camera measurements)
  • Subjects with amputated index fingers (for camera measurements) or amputated upper limb;
  • Subjects below 21 years old and above 85 years old.

Treatment and study plan

Lifestyle survey completion

Other

For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.

Unlimited on-demand blood pressure measurements with G2C

Other

For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated

Continual blood pressure measurements with G1

Other

For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.

Primary outcomes

  1. Multivariate models relating data from 24/7 Aktiia the G1 device continual BP monitoring with sociodemographic - lifestyle - and health factors

    Time frame: 10 years

    Strength and direction of the correlation coefficient between continuous blood pressure readings and various survey-derived factors such as sociodemographic variables, lifestyle habits, and health metrics.

Secondary outcomes

  1. Global scale projections of the benefit of the early awareness of hypertension with the spot-check Aktiia G2C device at the fingertip

    Time frame: 10 years

    Proportion of subjects with early hypertension awareness enabled by the fingertip spot-check feature of the Aktiia G2C device.

Study contacts

Contact information is provided by the study sponsor or research team.

Pascale Vermare

CONTACT

[email protected]

+41 32 552 20 52

Sponsors and collaborators

Lead sponsor

Aktiia SA

Industry

Registry information

Official study title

OBPM_FORESEE2024: Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk in a Multi-ethnic European Population: an Observational Cohorts' Study

Acronym: FORESEE2024

Important dates

Study start
2025
Primary completion
2035
Study completion
2035
First posted
Nov 1, 2024
Registry last updated
May 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.